Prognostic Value of Baseline Systemic Immune-Inflammation Index in Advanced Intrahepatic Cholangiocarcinoma Treated with First-Line Gemcitabine–Cisplatin Plus PD-L1 Inhibitor: A Single-Center Retrospective Study.
Simple Summary: Bile duct cancer that starts inside the liver is difficult to treat, and people can respond very differently to the same medicines. Doctors need simple and inexpensive ways to identify patients who may do better or worse before treatment begins. In this study, we reviewed the medical...
| Publicado en: | Current Oncology Vol. 31; no. 2; pp. 123 - 138 |
|---|---|
| Autores principales: | , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Feb2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |